Julian Topaly

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

Julian Topaly, WJ Zeller, Stefan Früehauf · Leukemia · 2001 · 173 citations

Medicine, Oncology, Pharmacology +13

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

Stefan Früehauf, Marlon R. Veldwijk, Timon Seeger et al. · Cytotherapy · 2009 · 123 citations

Life Sciences, Hematology, Immunology +17

Development and Optimization of a Real-Time Quantitative PCR-Based Method for the Titration of AAV-2 Vector Stocks

Marlon R. Veldwijk, Julian Topaly, Stephanie Laufs et al. · Molecular Therapy · 2002 · 108 citations · Full text

Life Sciences, Molecular Biology, Gene Therapy +12

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG

Aleksandar Radujkovic, M Schad, Julian Topaly et al. · Leukemia · 2005 · 92 citations

Medicine, Oncology, Pharmacology +6

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients

Stefan Früehauf, Gerhard Ehninger, Kai Hübel et al. · Bone Marrow Transplantation · 2009 · 69 citations

Medicine, Hematology, Oncology +17